AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30179569
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (Bv) and AVD chemotherapy
Trial: 30180050
Drug: Uterosacral ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterosacral ligament suspension (USLS) with a size 'small' titanium vascular clip applied to the base of each suture.
Trial: 30181045
Drug: Double-dose (DD)
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-dose (DD) influenza vaccine (30 µg antigen)
Trial: 30181045
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) influenza vaccine (15 µg antigen)
Trial: 30181172
Drug: Additional agents
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional agents tailored by disease severity
Trial: 30181185
Drug: Violet LED
RxNorm normalized name: acid violet 43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Violet LED treatment (405 nm)
Trial: 30185228
Drug: pictilisib (GDC-0941)
RxNorm normalized name: calcium carbonate
DrugBank: Pictilisib (DB11663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pictilisib (GDC-0941) plus paclitaxel (90 mg/m²)
Trial: 30185431
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) 25 mg/m2
Trial: 30186623
Drug: Fimasartan (Kanarb),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (Kanarb), switched to after 8 weeks of treatment
Trial: 30187270
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (HFNT)
Trial: 30187599
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a 180 μg/wk added to ongoing nucleos(t)ide analogue therapy
Trial: 30188978
Drug: Allometric miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allometric miltefosine dosing for 28 days
Trial: 30188978
Drug: Linear miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linear miltefosine dosing (2.5 mg/kg/day for 28 days)
Trial: 30190299
Drug: Regorafenib-related treatment-emergent
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib-related treatment-emergent adverse events (TEAEs)
Trial: 30190302
Drug: TRC105 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib (initially at 5 mg b.i.d. and escalated to a maximum of 10 mg b.i.d.)
Trial: 30190302
Drug: TRC105 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib
Trial: 30191053
Drug: Hepatic intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hepatic intra-arterial chemotherapy (IACHT) with Epirubicin-Cisplatin and systemic chemotherapy (SCHT) with Capecitabine or 5-fluorouracil, followed by gemcitabine-based maintenance therapy.
Trial: 30191502
Drug: Behavioral/pharmacological treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral/pharmacological treatment
Trial: 30191523
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg orally three times daily plus hydrocortisone (20 mg in the morning and 10 mg at night) and lenalidomide 25 mg orally daily for 21 days in a 28-day cycle and aspirin 75 mg daily
Trial: 30191864
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with a dose of 40 Gy in 5 fractions of 8 Gy
Trial: 30192444
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (maximum dose of 21.0 mg/d, applied daily with dose escalation)
Trial: 30194585
Drug: Single 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 40 mg oral dose of imarikiren
Trial: 31203649
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Treatment for Insomnia (BBTi)
Trial: 30196853
Drug: AAV8-RS1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e9 vg/eye
Trial: 30196853
Drug: AAV8-RS1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e10 vg/eye
Trial: 30196853
Drug: AAV8-RS1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e11 vg/eye
Trial: 30198934
Drug: Alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 10 µg·kg(-1)
Trial: 30199593
Drug: All-oral DAA
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-oral DAA combinations
Trial: 30200905
Drug: HIV self-testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV self-testing (HIVST) conducted by MSM, either finger prick or oral fluid, without assistance from a trained counselor
Trial: 30200905
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid HIV self-testing
Trial: 30201761
Drug: Avadomide (CC-122)
RxNorm normalized name: Avadomide
DrugBank: Avadomide (DB14857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avadomide (CC-122) at doses ranging from 0.5-3.5 mg, 28-day continuous dosing cycles
Trial: 30201761
Drug: Avadomide (CC-122)
RxNorm normalized name: Avadomide
DrugBank: Avadomide (DB14857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avadomide (CC-122)
Trial: 30201849
Drug: Combined immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunosuppressive therapy (rituximab, high-dose pulsed steroids, cyclophosphamide until remission, followed by maintenance therapy with azathioprine)
Trial: 30201849
Drug: Combined immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunosuppressive therapy
Trial: 30203081
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of Takeda's bivalent norovirus virus-like particle (VLP) vaccine candidate
Trial: 30204542
Drug: Maternal milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal milk lutein concentrations (sample 1: 6.5 μg/dL, sample 2: 7.7 μg/dL)
Trial: 30204542
Drug: Maternal milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal milk zeaxanthin concentrations (sample 1: 1.6 μg/dL, sample 2: 1.7 μg/dL)
Trial: 30204885
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS-PL) with 20 mg Fe
Trial: 30204885
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA) with 60 mg Fe + 400 µg folic acid
Trial: 30205124
Drug: Metastasis-directed stereotactic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastasis-directed stereotactic body radiation therapy (mdSBRT)
Trial: 30205231
Drug: Ruxolitinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib therapy followed by reduced-intensity conditioning (RIC) regimen
Trial: 30205886
Drug: IV sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sodium nitrite 25 mg (low dose)
Trial: 30205886
Drug: IV sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sodium nitrite 60 mg (high dose)
Trial: 30205886
Drug: IV sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sodium nitrite (both doses)
Trial: 30207748
Drug: Technosphere insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technosphere insulin (TI), n=26
Trial: 30207748
Drug: Technosphere insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technosphere insulin (TI) compliant group (n=15)
Trial: 30207748
Drug: Insulin aspart,
RxNorm normalized name: insulin aspart, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin aspart, n=34
Trial: 30208209
Drug: Continued appropriate
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued appropriate medical therapy (CAMT)
Trial: 30209556
Drug: Gemcitabine, cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, cisplatin, and dexamethasone (GDP) combined with methotrexate (MTX) and pegaspargase (PEG-L)
Trial: 30212436
Drug: Inguinal lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inguinal lymph node biopsy at baseline and/or after antiretroviral therapy (median 48 weeks after therapy)
Trial: 30213581
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of baseline concentrations of COL3A1 and anti-CSF2
Trial: 31576181
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants (TTI)
Trial: 30214408
Drug: Adjunctive everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive everolimus (Low exposure: 3-7 ng/mL)
Trial: 30214408
Drug: Adjunctive everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive everolimus (High exposure: 9-15 ng/mL)
Trial: 30216219
Drug: CTC-positive (≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC-positive (≥1 CTC/7.5 mL) in high-risk patients
Trial: 30217223
Drug: Transcatheter delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter delivery of autologous bone marrow-derived advanced therapy medicinal product CD133
Trial: 30217228
Drug: Salvianolate injection
RxNorm normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvianolate injection
Trial: 30217671
Drug: Trabectedin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin and olaparib combination treatment
Trial: 30219274
Drug: Immunocryosurgery (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunocryosurgery (5% imiquimod cream daily for five weeks and cryosurgery on day fourteen)
Trial: 30219367
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine in pregnant women
Trial: 30219367
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine in nonpregnant women
Trial: 30219367
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine in pregnant women and nonpregnant women
Trial: 30219858
Drug: l-carnitine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine treatment
Trial: 30219858
Drug: no l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no l-carnitine treatment
Trial: 30221011
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and sildenafil (100 mg by mouth daily during therapy, three times daily on the day of doxorubicin)
Trial: 30221011
Drug: Standard doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doxorubicin chemotherapy alone
Trial: 30221150
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg EOW
Trial: 30222972
Drug: EUS-guided photodynamic
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS-guided photodynamic therapy (PDT) with intravenous porfimer sodium followed by EUS-PDT
Trial: 30223771
Drug: DelApp smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DelApp smartphone application for assessing inattention in delirium, administered within 3 hours of reference standard assessment.
Trial: 30224193
Drug: Ertugliflozin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin (15 mg single oral dose)
Trial: 30224284
Drug: Metformin, pioglitazone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, pioglitazone, and lifestyle therapy
Trial: 30224284
Drug: Metformin, pioglitazone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, pioglitazone, GLP-1 receptor agonist, and lifestyle therapy
Trial: 30224284
Drug: Lifestyle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle therapy only
Trial: 30224322
Drug: No neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neuromuscular blocking agents
Trial: 30224333
Drug: Limbr mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limbr mobile phone app suite including daily visual self-reports, rehabilitation video tutorials, passive activity-level measurement, and chat-based health coaching.
Trial: 30224333
Drug: Your Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Your Activities of Daily Living module
Trial: 30224393
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg tablets prescribed
Trial: 30224393
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg tablets for musculoskeletal pain
Trial: 30224393
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg tablets for fracture
Trial: 30224393
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg tablets for renal colic or abdominal pain
Trial: 30224393
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg tablets for other pain conditions
Trial: 30224393
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg tablets for first 3 days
Trial: 30224926
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine ICH-012 (8 herbal medicines including Hirudo and Tabanus)
Trial: 30224926
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine ICH-012
Trial: 30225601
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with gemcitabine (GEM) 1000 mg/m² for three cycles followed by gemcitabine-erlotinib and radiotherapy
Trial: 30225844
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral immunotherapy (OIT) with biweekly dose step-up until reaching maximum maintenance dose (MMD) of 5000 mg peanut protein or individual maintenance dose (IMD).
Trial: 30225844
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral immunotherapy (OIT)
Trial: 30227072
Drug: MEDI-551, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-551, an anti-CD 19 B-cell depleting monoclonal antibody, administered for up to 197 days
Trial: 30227856
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy at month 3
Trial: 30227856
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy at month 1
Trial: 30227856
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy at baseline
Trial: 30227886
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg tremelimumab at 90 day intervals
Trial: 30227893
Drug: brachyury-targeted antitumor
RxNorm normalized name: BN-Brachyury vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, IL-15 agonist, IDO1 inhibitor
Trial: 30228904
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of clarithromycin treatment
Trial: 30229280
Drug: CT-P13 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46, with increased dose of 1.5 mg/kg for inadequate response from week 14 to week 46.
Trial: 30229280
Drug: CT-P13 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 treatment
Trial: 30230263
Drug: Inhaled batefenterol
RxNorm normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled batefenterol
Trial: 30230947
Drug: JE-CV booster
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV booster dose in children
Trial: 30230947
Drug: JE-CV single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV single dose primary vaccination in toddlers
Trial: 30231665
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg [14C]-MT-1303
Trial: 30231854
Drug: MRI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI and CTC assessments during radiation therapy
Trial: 30231854
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CTCs and MRI
Trial: 30232146
Drug: Selective Indoleamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003
Trial: 30232224
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg twice daily for 7 days every 21 days
Trial: 30232558
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg orally once daily until disease progression or unacceptable toxicity
Trial: 30232616
Drug: Intraoperative probe-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative probe-based confocal laser endomicroscopy (pCLE) with near-infrared illumination and indocyanine green as contrast agent.
Trial: 30233140
Drug: nimesulide/pantoprazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide/pantoprazole (100 mg/20 mg) twice daily for 14 days
Trial: 30233140
Drug: naproxen/esomeprazole magnesium
RxNorm normalized name: naproxen/esomeprazole magnesium 375 mg-20 mg ORAL TABLET,IMMEDIATE,DELAY RELEASE,BIPHASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen/esomeprazole magnesium (500 mg/20 mg) twice daily for 14 days
Trial: 30233802
Drug: Pirfenidone 801
RxNorm normalized name: pirfenidone 801 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone 801 mg three times daily for 24 weeks
Trial: 30233808
Drug: Salbutamol (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (900 µg)
Trial: 30234000
Drug: Fitbit-Plus (activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitbit-Plus (activity trackers + weekly emails)
Trial: 30234419
Drug: HAT TRICK
RxNorm normalized name: hATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAT TRICK program (12 weekly sessions promoting healthy eating, active living, and social connectedness)
Trial: 30234617
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (APDs)
Trial: 30235235
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil 10 mg
Trial: 30235940
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) adherence measured by time-to-refill